The earnings call reflected a strong quarter characterized by significant growth in FILSPARI sales, potential FDA approval for new indications, and successful manufacturing advancements. However, seasonal trends and a competitive market present challenges.

Company Guidance

During the Travere Therapeutics' Third Quarter 2025 Financial Results Conference Call, substantial progress was highlighted across multiple fronts. The company achieved approximately $91 million in net product sales for FILSPARI in the third quarter, marking a more than 155% year-over-year increase, driven by robust demand and strong physician adoption. The FDA's modification of the FILSPARI REMS program and its inclusion in the KDIGO guidelines have been pivotal, simplifying monitoring requirements and reinforcing confidence in FILSPARI's safety profile. Internationally, partners like CSL Vifor have expanded access in Europe, resulting in a meaningful market access milestone. In Japan, Renalys completed enrollment for an IgAN trial. Additionally, Travere is preparing for a potential FDA approval for FILSPARI in FSGS, which would position it as the first approved medication for this condition. The company achieved a net income of $25.7 million, with SG&A expenses increasing to $86.5 million due to preparation for the FSGS launch and continued investment in FILSPARI's commercialization.

FILSPARI Growth in IgA Nephropathy

FILSPARI net product sales reached approximately $91 million in the third quarter, representing an increase of more than 155% year-over-year, driven by consistent demand and deepening engagement among prescribers.

FDA Approval and Global Expansion Efforts

In August, the FDA approved a modification to the FILSPARI REMS program, simplifying care and reinforcing safety. Additionally, strong progress was made in Europe, the U.K., and Japan with regulatory approvals and trial advancements.

Potential FDA Approval for FSGS

Pending FDA approval, FILSPARI could become the first approved medication for FSGS, offering a transformative opportunity for Travere and addressing a significant unmet medical need.

Progress in Pegtibatinase Manufacturing

Successfully manufactured the first commercial scale batches of pegtibatinase, positioning for the restart of the pivotal HARMONY study in 2026.

Strong Financial Performance

Net income for the third quarter of 2025 was $25.7 million, compared to a net loss in the same period the previous year, showcasing strong financial growth.

Travere Therapeutics (TVTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TVTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2025 (Q4)	-0.07 / -	-0.73	―	―	―
Oct 30, 2025	2025 (Q3)	-0.30 / 0.28	-0.7	140.00% (+0.98)
Aug 06, 2025	2025 (Q2)	-0.31 / -0.14	-0.91	84.62% (+0.77)	―
May 01, 2025	2025 (Q1)	-0.57 / -0.47	-1.76	73.30% (+1.29)	―
Feb 20, 2025	2024 (Q4)	-0.56 / -0.73	-1.18	38.14% (+0.45)	―
Oct 31, 2024	2024 (Q3)	-0.67 / -0.70	1.97	-135.53% (-2.67)	―
Aug 01, 2024	2024 (Q2)	-0.79 / -0.91	-1.13	19.47% (+0.22)	―
May 06, 2024	2024 (Q1)	-0.96 / -1.76	-1.27	-38.58% (-0.49)	―
Feb 15, 2024	2023 (Q4)	-1.16 / -1.18	-1.03	-14.56% (-0.15)	―
Nov 07, 2023	2023 (Q3)	-1.06 / 1.97	-1.09	280.73% (+3.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TVTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 30, 2025	$29.65	$35.16	+18.58%
Aug 06, 2025	$17.24	$16.91	-1.91%
May 01, 2025	$20.76	$21.15	+1.88%
Feb 20, 2025	$23.58	$21.98	-6.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Travere Therapeutics (TVTX) report earnings?

Travere Therapeutics (TVTX) is schdueled to report earning on Feb 19, 2026, After Close (Confirmed).

What is Travere Therapeutics (TVTX) earnings time?

Travere Therapeutics (TVTX) earnings time is at Feb 19, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TVTX EPS forecast?

TVTX EPS forecast for the fiscal quarter 2025 (Q4) is -0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing